In addition to being involved in the white-hot medical marijuana industry through its partner, Medicated Markets International, Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH) has taken steps to add something to the vitally important arena of women’s health.
It has been a focus for the company for quite some time, but a new development has arisen, with the publishing of a fresh PR this morning. The news comes on the heels of a bullish session yesterday wherein shares of EAPH rose form a low of .025 to .031.
Per the release, Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH) has announced the appointment of Dr. Jose Tiran to head up its Women’s Health Medical/Scientific Advisory Board. Dr. Tiran will advise the company and its partners on matters pertaining to the launch of a line of women’s health products. He is a Fellow of the American College of Obstetricians and Gynecologists, and a board-certified practitioner in Mexico.
Dr. Tiran stated, “I am very excited to be part of the program for these soon-to-be-launched women’s health and treatment products in the hope of providing to Latin American women the same choices they have in the US and Europe. We have a huge unmet medical need in Latin America for these kind of alternative diagnostic and treatment products. The vaginal discharge diagnostic test will facilitate a woman’s ability to determine the causative agent; the natural lactic acid treatment gel will provide a new, non-toxic treatment option, and put Latin American women on a par with North American and European women. The professional version of this diagnostic test will also enable the gynecologist to increase the accuracy in the differential diagnosis of vaginal discharge, right in the gynecologist’s office, something currently lacking in Latin America. The natural lactic acid gel treatment expected to launch in parallel with the diagnostic will be offered to women who test positive for bacterial infection and is a significant treatment option advance since it could obviate the need for potential use of antibiotics and further presence of bacterial resistance, so this is a promising and exciting development for the future of women’s health.”
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica SA de C.V. and together, own the exclusive distribution rights in Mexico and Latin America for patented women’s diagnostic and preventative care products from CommonSense of Israel, along with two generic cancer drugs, Paclitaxel and Docetaxel from BioLyse Pharma of St. Catherine’s Ontario, Canada. The company’s list of woman’s diagnostic, treatment and preventative care products include, Gynofit, licensed from a Swiss based manufacturer, VS-Sense and AmnioSense, both patented products that are licensed from Israel based CommonSense.
Easton Pharmaceuticals announced in December that its partner BMV Medica SA de C.V. through its host company Ackerman Pharma, had signed a Sales & Marketing Agreement with Gedeon Richter Mexico S.A.P.I. de C.V. a Mexican-based company and affiliate of Gedeon Richter Plc, for Easton / BMV’s “Gynofit” Lactic Acid Gel for the treatment of Bacterial Vaginosis in Mexico. Then, in the first week of 2017, announced that it had received the first purchase agreement to distribute the treatment in Mexico. (Via: EastonPharmceuticalsInc.com)
We’re interested to continue following EAPH as it actively pursues progress in the area of women’s health. Get signed up for our 100% free newsletter today and keep up to date on this and many other interesting stories. We’ll stay tuned to the story and report any new developments here on StreetRegister.com. Sign up now for our 100% free newsletter! Add your information to our database now. Just enter your email in the subscribe box below!